NEW YORK (Reuters Health)—The interleukin 23 inhibitor guselkumab is associated with more improvement in psoriasis on the scalp, palms and/or soles compared with adalimumab, a new analysis suggests. Andrew Blauvelt, MD, MBA, of Oregon Medical Research Center in Portland conducted a secondary analysis of data from the international VOYAGE 1 and VOYAGE 2 studies, double-blind,… [Read More]
Search results for: psoriasis
Risankizumab Promising for Psoriasis; Plus Canada Approves Brodalumab

Two Phase 3 clinical trials show that risankizumab is effective for achieving skin clearance in patients with psoriasis…... [Read More]
Ixekizumab Promising for AS; Plus Certolizumab Pegol Studied for Psoriasis

In a Phase 3 study, ixekizumab proved safe and effective to treat adults with ankylosing spondylitis (AS)…... [Read More]
Secukinumab Promising for Sustained Improvements in Palmoplantar & Nail Psoriasis

In clinical trials, secukinumab proved safe and effective as a long-term treatment for both palmoplantar and nail psoriasis…... [Read More]
Psoriasis Tied to Higher Risk of Serious Liver Disease
(Reuters Health)—People with chronic inflammatory disorders, such as psoriasis and rheumatoid arthritis (RA), may have an increased risk of developing serious liver damage, a recent study suggests. These inflammatory disorders are often treated with methotrexate, a medication linked to an increased risk of liver disease. For the current study, researchers followed more than 1 million… [Read More]
Rheumatology Drug Updates: Efficacy Studied Following Accelerated Drug Approvals; Plus Secukinumab Meets Benchmark for Psoriasis

Medications for serious or life-threatening conditions may receive accelerated approval from the U.S. Food and Drug Administration (FDA) by showing an effect on surrogate measures that are reasonably likely to predict a treatment’s clinical benefit. Post-approval confirmatory drug trials are then required to determine whether or not these effects translate into clinical improvements. In recent… [Read More]
Ustekinumab Approved for Use in Adolescents with Plaque Psoriasis

In October, the FDA approved ustekinumab to treat patients 12 years or older who have moderate to severe plaque psoriasis…... [Read More]
Secukinumab Meets 5-Year Benchmark for Psoriasis

In an extension study, nearly half the patients with plaque psoriasis taking secukinumab maintained skin clearance for the five years of the study…... [Read More]
Beyond Awareness: August Is Psoriasis Action Month

This month, the National Psoriasis Foundation is urging patients and rheumatologists to take charge of psoriatic disease by setting ambitious treatment goals to achieve better health outcomes…... [Read More]
Molecular Differences Between Pediatric & Adult Psoriasis Plaques
NEW YORK (Reuters Health)—The pathology of pediatric psoriasis differs from that of adult psoriasis, a finding that has implications for treatment, researchers suggest. “Pediatric psoriasis often differs from adult psoriasis in presentation, triggers, natural history, and response to therapy, suggesting potential differences in the pathophysiology of the disease processes,” Dr. Kelly Cordoro of the University… [Read More]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 43
- Next Page »